Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

158 THE PREMENSTRUAL SYNDROMES
premenstrual dysphoric disorder: a study of treatment processes.
J Psychosom Res 2002; 53(3):811–17.
31. Christensen AP, Oei TPS. The efficacy of cognitive behavior
therapy in treating premenstrual dysphoric changes. J Affect
Disord 1995; 33:57–63.
32. Blake F, Salkovskis P, Gath D et al. Cognitive therapy for premenstrual
syndrome: a controlled trial. J Psychosom Res 1998;
45(4):307–18.
33. Kurshan N, Epperson CN. Oral contraceptives and mood in
women with and without premenstrual dysphoria: a theoretical
model. Arch Womens Ment Health 2006; 9:1–14.
34. Freeman EW, Kroll R, Rapkin A et al; PMS/PMDD Research
Group. Evaluation of a unique oral contraceptive in the treatment
of premenstrual dysphoric disorder. J Womens Health Gend
Based Med 2001; 20:561–96.
35. Apter D, Borsos A, Baumgartner W et al. Effect of an oral
contraceptive containing drospirenone and ethinylestradiol on
general well-being and fluid-related symptoms. Eur J Contracept
Reprod Health Care 2003; 8:37–51.
36. Foidart JM, Wuttke W, Bouw GM et al. A comparative investigation
of contraceptive reliability, cycle control and tolerance of two
monophasic oral contraceptives containing either drospirenone or
desogestrel. Eur J Contracept Reprod Health Care 2000;
5:124–34.
37. Sangthawan M, Taneepanichskul S. A comparative study of
monophasic oral contraceptives containing either drospirenone
3 mg or levonorgestrel 150 �g on premenstrual symptoms.
Contraception 2005; 71:1–7.
38. Borenstein J, Yu HT, Wade S et al. The effect of an oral contraceptive
containing ethinyl estradiol and drospirenone (Yasmin) on
premenstrual symptomatology and health-related quality of life. J
Reprod Med 2003; 48(2):79–85.
39. Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new lowdose
oral contraceptive with drospirenone in premenstrual
dysphoric disorder. Obstet Gynecol 2005; 106(3):492–501.
40. Pearlstein TB, Bachmann GA, Zacur HA et al. Treatment of premenstrual
dysphoric disorder with a new drospirenone-containing
oral contraceptive formulation. Contraception 2005; 72:414–21.
41. Steiner M, Steinberg S, Stewart D et al. Fluoxetine in the treatment
of premenstrual dysphoria. N Engl J Med 1995; 332:
1529–34.
42. Freeman EW, Rickels K, Arredondo F et al. Full or half-cycle
treatment of severe premenstrual syndrome with a serotonergic
antidepressant. J Clin Psychopharmacol 1999; 19:3–8.
43. Wikander I, Sundblad C, Andersch B et al. Citalopram in premenstrual
dysphoria: is intermittent treatment during luteal
phases more effective than continuous medication throughout the
menstrual cycle? J Clin Psychopharmacol 1998; 18:390–8.
44. Freeman EW, Rickels K, Yonkers KA et al. Venlafaxine in the
treatment of premenstrual dysphoric disorder. Obstet Gynecol
2001; 98:737–44.
45. Pearlstein TB, Stone AB, Lund SA et al. Comparison of fluoxetine,
bupropion, and placebo in the treatment of premenstrual
dysphoric disorder. J Clin Psychopharmacol 1997; 17:261–6.
46. Wyatt KM, Dimmock PW, O’Brien PMS. Selective serotonin
reuptake inhibitors for premenstrual syndrome. Cochrane
Database Syst Rev 2002; (4):CD001396.
47. Halbreich U, Smoller JW. Intermittent luteal phase sertraline
treatment of dysphoric premenstrual syndrome. J Clin Psychiatry
1997; 58:399–402.
48. Halbreich U, Bergeron R, Yonkers KA et al. Efficacy of intermittent,
luteal phase sertraline treatment of premenstrual dysphoric
disorder. Obstet Gynecol 2002; 100(6):1219–29.
49. Freeman EW, Rickels K, Sondheimer SJ et al. Continuous or intermittent
dosing with sertraline for patients with severe
premenstrual syndrome or premenstrual dysphoric disorder. Am J
Psychiatry 2004; 161(2):343–51.
50. Miner C, Brown E, McCray S et al. Weekly luteal-phase dosing
with enteric-coated fluoxetine 90 mg in premenstrual dysphoric
disorder: a randomized, double-blind, placebo-controlled clinical
trial. Clin Ther 2002; 24(3):417–33.
51. Freeman EW, Sondheimer SJ, Sammel MD et al. A preliminary
study of luteal phase versus symptom-onset dosing with escitalopram
for premenstrual dysphoric disorder. J Clin Psychiatry
2005; 66:769–73.
52. Freeman EW. Luteal phase administration of agents for the treatment
of premenstrual dysphoric disorder. CNS Drugs 2004;
18(7):453–68.
53. Cohen LS, Soares CN, Yonkers KA et al. Paroxetine controlled
release for premenstrual dysphoric disorder: a double-blind,
placebo-controlled trial. Psychosom Med 2004; 66(5):707–13.
54. Steiner M, Brown P, Trzepacz J et al. Fluoxetine improves functional
work capacity in women with premenstrual dysphoric
disorder. Arch Womens Ment Health 2003; 6(1):71–7.
55. Ferguson JM. The effects of antidepressants on sexual functioning
in depressed patients: a review. J Clin Psychiatry 2001; 62(Suppl 3):
22–34.
56. Sundstrom-Poromaa I, Bixo M, Bjorn I et al. Compliance to antidepressant
drug therapy for treatment of premenstrual syndrome.
J Psychosom Obstet Gynaecol 2000; 21:205–11.
57. Hirschfeld RM. Long-term side effects of SSRIs: sexual dysfunction
and weight gain. J Clin Psychiatry 2003; 64(Suppl 18):20–4.
58. Zajecka J. Strategies for the treatment of antidepressant-related
sexual dysfunction. J Clin Psychiatry 2001; 62(Suppl 3):35–43.
59. Dillon AJ, for GlaxoSmithKline, Inc., endorsed by Health
Canada, new safety information regarding paroxetine. Findings
suggest increased risk over other antidepressants, of congenital
malformations, following first trimester exposure to paroxetine.
Available: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/
paxil_3_hpc-cps_e.html.
60. Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late
in utero exposure to serotonin reuptake inhibitors. JAMA 2005;
293:2372–83.
61. Landen M, Eriksson O, Sundblad C et al. Compounds with affinity
or serotonergic receptors in the treatment of premenstrual dysphoria:
a comparison of buspirone, nefazodone and placebo.
Psychopharmacologia 2001; 155:292–8.
62. Ginsburg KA, Dinsay R. Premenstrual syndrome. In: Ransom SB,
ed. Practical Strategies in Obstetrics and Gynecology. Philadelphia:
WB Saunders; 2000:684–94.
63. Vellacott ID, Shroff NE, Pearce MY et al. A double-blind,
placebo-controlled evaluation of spironolactone in the premenstrual
syndrome. Curr Med Res Opin 1987; 10:450–6.
64. Wang M, Hammarback S, Lindhe BA et al. Treatment of premenstrual
syndrome by spironolactone: a double-blind, placebo-controlled
study. Acta Obstet Gynecol Scand 1995; 74:803–8.
65. Muse KN, Cetel NS, Futterman LA et al. The premenstrual
syndrome – effects of ‘medical ovariectomy.’ N Engl J Med 1984;
311:1345–9.
66. Mortola JF, Girton L, Fischer U. Successful treatment of severe
premenstrual syndrome by combined use of gonadotropin-releasing
hormone agonist and estrogen/progestin. J Clin Endocrinol
Metab 1991; 71:252a–f.
67. Mezrow G, Shoupe D, Spicer D et al. Depot leuprolide acetate
with estrogen and progestin add-back for long-term treatment of
premenstrual syndrome. Fertil Steril 1994; 62:932–7.
68. Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O’Brien PM.
The effectiveness of GnRHa with and without ‘add-back’ therapy
in treating premenstrual syndrome: a meta analysis. BJOG 2004;
111(6):585–93.